Community Regional Trauma and Burn Center
Fresno, California, 93721, United States
NCT Number: NCT03676816
Consenting adult female patient felt by the provider to require gonorrhea/chlamydia endocervical testing will be asked to provide an additional self sample specimen. The specimen will be sent to the laboratory using conventional diagnostic test for gonorrhea/chlamydia.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Fresno, California, 93721, United States
Study protocol:
a. Provider identifies patient who is felt to require gonorrhea/chlamydia testing.
i. Provider will contact study staff to consent patient. b. Study staff identifies patient who is felt by provider to require gonorrhea/chlamydia testing. i. Study staff will ask provider if they could move forward with consenting patient.
c. Provider who is study staff identifies patient who is felt to require gonorrhea/chlamydia testing.
a. The collection container is sent to the lab, and the final result is noted in the medical record as per standard practice (standard procedure).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This is a prospective, non-inferiority trial comparing two methods of collection using a US Food and Drug Administration- cleared 90-minute rapid nucleic acid amplification assay, the Xpert CT/NG assay. Any adult female patient admitted to the Emergency Department at Community Regional Medical Center felt by the provider to require gonorrhea/chlamydia endocervical testing may be entered in the study.
Other names: Cepheid, SWAB/A-50
provider-performed endocervical sampling is the gold standard for both gonorrhea and chlamydia. The provider takes a endocervical sample which will get sent to the laboratory as the standard care in comparison to the device being studied.
Time frame: 2-3 days
In order for vaginal self-sampling to be considered clinically noninferior to the standard provider-performed endocervical sampling method of collection, we established a minimum sensitivity of 90%. This was based on previous research showing Sexually Transmitted Infection (STI) clinicians' top priority for a point of care STI test is a minimum sensitivity of 90%. In addition, a previous ED study examining urine gonorrhea/chlamydia diagnosis using the same point of care test as this study also used a minimum sensitivity of 90%. (9) Thus, our primary outcome measure was examining for the noninferiority of VSS sensitivity for gonorrhea/chlamydia, with noninferiority being demonstrated if the sensitivity is >=90%.
Time frame: 2-3 days
Vaginal self-sampling specificity, positive predictive value, negative productive value for gonorrhea/chlamydia (measured by individual patient)
Time frame: 2-3 days
Vaginal self-sampling sensitivity, specificity, positive predictive value, negative predictive value for gonorrhea
Time frame: 2-3 days
Vaginal self-sampling sensitivity, specificity, positive predictive value, negative predictive value for chlamydia
Time frame: 2-3 days
Concordance of vaginal self-sampling to provider-performed endocervical sampling
Time frame: 2-3 days
Acceptance rate vaginal self-sample
Time frame: 2-3 days
Rate of patients worried about doing vaginal self-sampling and correctly
Time frame: 2-3 days
Rate of patients that prefer vaginal self-sample to provider-performed endocervical sampling
Time frame: 2-3 days
Number of patients that refused vaginal self-sampling
Time frame: 2-3 days
Description of reasons for refusal of vaginal self-sampling
University of California, San Francisco
Other
Vaginal Self-sampling for Rapid Turnaround Gonorrhea/Chlamydia Testing in the Emergency Department
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01665690
Bacterial Infections, Bacterial Infections and Mycoses
Olympia, Washington, United States
View Trial DetailsNCT00978848
Bacterial Infections, Bacterial Infections and Mycoses
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT04446611
Acquired Immunodeficiency Syndrome, Antenatal Care
East London, Eastern Cape, South Africa
View Trial DetailsNCT00207454
Chlamydia Trachomatis, Neisseria Gonorrhoeae
Brooklyn, New York, United States
View Trial Details